keyword
https://read.qxmd.com/read/38644857/molecular-modelling-and-anticholinesterase-activity-of-the-essential-oil-from-three-chemotypes-of-lippia-alba-mill-n-e-br-ex-britton-p-wilson-verbenaceae
#1
JOURNAL ARTICLE
Antônio Quaresma Silva Júnior, Gabriela Dos Santos Rodrigues, Karina Alcântara de Sousa, Leoneide Erica Maduro Bouillet, Gabriela Bianchi Dos Santos, Adenilson de Sousa Barroso, Rosa Helena Veras Mourão
Lippia alba (Mill.) N.E. Brown (Verbenaceae), popularly known as "erva cidreira", is one of the most used plants in Brazilian folk medicine. The species has several chemotypes and its volatile constituents have already been characterized, and present different chemical markers with known pharmacological properties, such as analgesic, sedative and antifungal properties. The objective of this study was to evaluate the anticholinesterase activity (AChE) of the essential oil of three chemotypes of Lippia alba and, by using molecular anchoring, determine the best receptor-ligand interaction energies of the main constituents present in the samples of oil...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38640937/mechanisms-and-management-of-loss-of-response-to-anti-tnf-therapy-for-patients-with-crohn-s-disease-3-year-data-from-the-prospective-multicentre-pants-cohort-study
#2
JOURNAL ARTICLE
Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Rebecca Smith, Christopher Roberts, Maria Bishara, Rachel Nice, Charlie W Lees, Shaji Sebastian, Peter M Irving, Richard K Russell, Timothy J McDonald, James R Goodhand, Tariq Ahmad, Nicholas A Kennedy
BACKGROUND: We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. METHODS: Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab and adalimumab in anti-TNF-naive patients with active luminal Crohn's disease aged 6 years and older...
April 16, 2024: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/38631003/overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma
#3
RANDOMIZED CONTROLLED TRIAL
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E Burgents, Rodolfo F Perini, Thomas Powles
BACKGROUND: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 1:1 ratio) participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks for up to 17 cycles (approximately 1 year) or until recurrence, the occurrence of unacceptable toxic effects, or withdrawal of consent...
April 18, 2024: New England Journal of Medicine
https://read.qxmd.com/read/38627249/ablef-antibody-language-ensemble-fusion-for-thermodynamically-empowered-property-predictions
#4
JOURNAL ARTICLE
Zachary A Rollins, Talal Widatalla, Andrew Waight, Alan C Cheng, Essam Metwally
MOTIVATION: Pre-trained protein language and/or structural models are often fine-tuned on drug development properties (ie, developability properties) to accelerate drug discovery initiatives. However, these models generally rely on a single structural conformation and/or a single sequence as a molecular representation. We present a physics-based model whereby 3D conformational ensemble representations are fused by a transformer-based architecture and concatenated to a language representation to predict antibody protein properties...
April 16, 2024: Bioinformatics
https://read.qxmd.com/read/38621392/associations-between-change-in-bmi-and-the-risk-of-hypertension-and-dyslipidaemia-in-people-receiving-integrase-strand-transfer-inhibitors-tenofovir-alafenamide-or-both-compared-with-other-contemporary-antiretroviral-regimens-a-multicentre-prospective-observational
#5
JOURNAL ARTICLE
Dathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella d'Arminio Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric Fontas, Irene Abela, Mario Sarcletti, Loveleen Bansi-Matharu, Nadine Jaschinski, Lars Peters, Sean R Hosein, Vani Vannappagari, Cal Cohen, Emiliano Bissio, Amanda Mocroft, Matthew Law, Lene Ryom, Kathy Petoumenos
BACKGROUND: Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts. However, whether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk of weight-related clinical events is unclear. We aimed to assess whether changes in BMI differentially increase hypertension or dyslipidaemia risk in people with HIV receiving INSTIs, tenofovir alafenamide, or both versus other contemporary regimens...
April 12, 2024: Lancet HIV
https://read.qxmd.com/read/38600625/hysterosalpingo-foam-sonography-versus-hysterosalpingography-during-fertility-work-up-an-economic-evaluation-alongside-a-randomized-controlled-trial
#6
JOURNAL ARTICLE
Danah Kamphuis, Rik van Eekelen, Nienke van Welie, Kim Dreyer, Joukje van Rijswijk, Machiel H A van Hooff, Jan Peter de Bruin, Harold R Verhoeve, Femke Mol, Wilhelmina M van Baal, Maaike A F Traas, Arno M van Peperstraten, Arentje P Manger, Judith Gianotten, Cornelia H de Koning, Aafke M H Koning, Neriman Bayram, David P van der Ham, Francisca P J M Vrouenraets, Michaela Kalafusova, Bob I G van de Laar, Jeroen Kaijser, Arjon F Lambeek, Wouter J Meijer, Frank J M Broekmans, Olivier Valkenburg, Lucy F van der Voet, Jeroen van Disseldorp, Marieke J Lambers, Rachel Tros, Cornelis B Lambalk, Jaap Stoker, Madelon van Wely, Patrick M M Bossuyt, Ben Willem J Mol, Velja Mijatovic
STUDY QUESTION: What are the costs and effects of tubal patency testing by hysterosalpingo-foam sonography (HyFoSy) compared to hysterosalpingography (HSG) in infertile women during the fertility work-up? SUMMARY ANSWER: During the fertility work-up, clinical management based on the test results of HyFoSy leads to slightly lower, though not statistically significant, live birth rates, at lower costs, compared to management based on HSG results. WHAT IS KNOWN ALREADY: Traditionally, tubal patency testing during the fertility work-up is performed by HSG...
April 10, 2024: Human Reproduction
https://read.qxmd.com/read/38588921/brachytherapy-for-rhabdomyosarcoma-survey-of-international-clinical-practice-and-development-of-guidelines
#7
JOURNAL ARTICLE
Raquel Dávila Fajardo, Giovanni Scarzello, Mark N Gaze, Tom Boterberg, Alison Cameron, Joerg Fuchs, Florent Guérin, Peter Hoskin, Matthew J Krasin, Petra Kroon, Henriette Magelssen, Claes Mercke, Johannes H M Merks, Frank Paulsen, Pascal Pommier, Monica Ramos, Helen Rees, Tim Rogers, Maximilian Schmid, Guido Seitz, Olga Slater, Naima Smeulders, Jakob Stenman, Sheila Terwisscha, Cyrus Chargari, Henry C Mandeville
BACKGROUND AND PURPOSE: The purpose of this study was to address the lack of published data on the use of brachytherapy in pediatric rhabdomyosarcoma by describing current practice as starting point to develop consensus guidelines. MATERIALS AND METHODS: An international expert panel on the treatment of pediatric rhabdomyosarcoma comprising 24 (pediatric) radiation oncologists, brachytherapists and pediatric surgeons met for a Brachytherapy Workshop hosted by the European paediatric Soft tissue Sarcoma Study Group (EpSSG)...
April 6, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38573025/pharmacokinetics-of-long-acting-cephapirin-and-cloxacillin-after-intramammary-administration-in-dairy-goats
#8
JOURNAL ARTICLE
Michelle P Buckley, Kristen P Hayman, Laura Burns, Dwayne Schrunk, Patrick J Gorden
Determining the pharmacokinetics of intramammary antimicrobials in goats can assist in predicting appropriate meat and milk withdrawal intervals for drugs that are effective at treating subclinical mastitis due to non-aureus Staphylococci during the dry period. Twenty-four healthy, lactating does were enrolled in this study. Half were administered 300 mg of cephapirin benzathine (ToMORROW, Boehringer Ingelheim Vetmedica, Duluth, GA) via intramammary infusion into each half of the udder. The remaining does had 500 mg cloxacillin benzathine (Orbenin DC, Merck & Co...
April 4, 2024: Journal of Veterinary Pharmacology and Therapeutics
https://read.qxmd.com/read/38561010/pembrolizumab-plus-concurrent-chemoradiotherapy-versus-placebo-plus-concurrent-chemoradiotherapy-in-patients-with-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-keynote-412-a-randomised-double-blind-phase-3-trial
#9
JOURNAL ARTICLE
Jean-Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Alves, Iane Pinto Figueiredo Lima, Brett G M Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pierre Delord, Ricard Mesía, Miren Taberna, John N Waldron, Christian Simon, Vincent Grégoire, Kevin J Harrington, Ramona F Swaby, Yayan Zhang, Burak Gumuscu, Behzad Bidadi, Lillian L Siu
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy...
March 29, 2024: Lancet Oncology
https://read.qxmd.com/read/38541079/evaluation-of-the-levels-of-selected-cytokines-and-their-possible-influence-on-the-development-of-cardiovascular-and-pulmonary-complications-in-patients-after-covid-19
#10
JOURNAL ARTICLE
Anita Stanjek-Cichoracka, Jacek T Niedziela, Anna Łaszewska, Zofia Mędrala, Alicja Nowowiejska-Wiewióra, Jacek Kaczmarski, Alicja Grzanka, Mariusz Gąsior
Background and Objectives : The aim of this study was to evaluate the levels of selected cytokines and their possible influence on the development of cardiovascular and pulmonary complications in patients hospitalized at the Silesian Centre for Heart Disease in Zabrze after having undergone COVID-19. Materials and methods : The study included 76 randomly selected patients from the SILCOVID-19 database. The median time from symptom onset to the study visit was 102 (86-118) days. The median age of the study group was 53 (44-60) years...
February 21, 2024: Medicina
https://read.qxmd.com/read/38538881/fda-approves-merck-co-s-pulmonary-arterial-hypertension-drug-sotatercept
#11
Katie Kingwell
No abstract text is available yet for this article.
March 27, 2024: Nature Reviews. Drug Discovery
https://read.qxmd.com/read/38521086/pembrolizumab-or-placebo-with-chemoradiotherapy-followed-by-pembrolizumab-or-placebo-for-newly-diagnosed-high-risk-locally-advanced-cervical-cancer-engot-cx11-gog-3047-keynote-a18-a-randomised-double-blind-phase-3-clinical-trial
#12
JOURNAL ARTICLE
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elias, Alejandro Acevedo, Vladyslav Sukhin, Noelle Cloven, Andrea J Pereira de Santana Gomes, Fernando Contreras Mejía, Ari Reiss, Ali Ayhan, Jung-Yun Lee, Valeriya Saevets, Flora Zagouri, Lucy Gilbert, Jalid Sehouli, Ekkasit Tharavichitkul, Kristina Lindemann, Roberta Lazzari, Chih-Long Chang, Rudolf Lampé, Hong Zhu, Ana Oaknin, Melissa Christiaens, Stephan Polterauer, Tomoka Usami, Kan Li, Karin Yamada, Sarper Toker, Stephen M Keefe, Sandro Pignata, Linda R Duska
BACKGROUND: Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy. In this phase 3 trial, we assessed the efficacy and safety of adding pembrolizumab to chemoradiotherapy in locally advanced cervical cancer. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 clinical trial, adults (age ≥18 years) at 176 medical centres in 30 countries with newly diagnosed, high-risk, locally advanced cervical cancer were randomly assigned (1:1) using an interactive voice-response system with integrated web response to receive 5 cycles of pembrolizumab (200 mg) or placebo every 3 weeks plus chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks...
March 20, 2024: Lancet
https://read.qxmd.com/read/38516107/tobacco-use-and-risk-of-acute-stroke-in-32-countries-in-the-interstroke-study-a-case-control-study
#13
JOURNAL ARTICLE
Xingyu Wang, Xin Liu, Martin J O'Donnell, Matthew McQueen, Allan Sniderman, Guillaume Pare, Graeme J Hankey, Sumathy Rangarajan, Siu Lim Chin, Purnima Rao-Melacini, John Ferguson, Denis Xavier, Hongye Zhang, Lisheng Liu, Prem Pais, Patricio Lopez-Jaramillo, Albertino Damasceno, Peter Langhorne, Annika Rosengren, Antonio L Dans, Ahmed Elsayed, Alvaro Avezum, Charles Mondo, Conor Judge, Hans-Christoph Diener, Danuta Ryglewicz, Anna Czlonkowska, Nana Pogosova, Christian Weimar, Romana Iqbal, Rafael Diaz, Khalid Yusoff, Afzalhussein Yusufali, Aytekin Oguz, Ernesto Penaherrera, Fernando Lanas, Okechukwu S Ogah, A Ogunniyi, Helle K Iversen, German Malaga, Zvonko Rumboldt, Shahram Oveisgharan, Fawaz Al Hussain, Yongchai Nilanont, Salim Yusuf
BACKGROUND: Smoking is a major risk factor for the global burden of stroke. We have previously reported a global population attributable risk (PAR) of stroke of 12.4% associated with current smoking. In this study we aimed to explore the association of current tobacco use with different types of tobacco exposure and environmental tobacco smoke (ETS) exposure on the risk of stroke and stroke subtypes, and by regions and country income levels. METHODS: The INTERSTROKE study is a case-control study of acute first stroke and was undertaken with 13,462 stroke cases and 13,488 controls recruited between January 11, 2007 and August 8, 2015 in 32 countries worldwide...
April 2024: EClinicalMedicine
https://read.qxmd.com/read/38498835/ovarian-response-and-embryo-ploidy-following-oral-micronized-progesterone-primed-ovarian-stimulation-versus-gnrh-antagonist-protocol-a-prospective-study-with-repeated-ovarian-stimulation-cycles
#14
JOURNAL ARTICLE
M Del Mar Vidal, Francisca Martínez, Ignacio Rodríguez, Nikolaos P Polyzos
STUDY QUESTION: Is there any difference in ovarian response and embryo ploidy following progesterone-primed ovarian stimulation (PPOS) using micronized progesterone or GnRH antagonist protocol? SUMMARY ANSWER: Pituitary downregulation with micronized progesterone as PPOS results in higher number of oocytes retrieved and a comparable number of euploid blastocysts to a GnRH antagonist protocol. WHAT IS KNOWN ALREADY: Although the GnRH antagonist is considered by most the gold standard protocol for controlling the LH surge during ovarian stimulation (OS) for IVF/ICSI, PPOS protocols are being increasingly used in freeze-all protocols...
March 18, 2024: Human Reproduction
https://read.qxmd.com/read/38496912/switch-to-generic-formulation-of-temozolomide-results-in-statistically-significant-increase-in-grade-3-and-4-bone-marrow-toxicity-in-glioma-patients-in-the-province-of-alberta
#15
JOURNAL ARTICLE
Egiroh Omene, Omar Abdel-Rahman, Eugene Batuyong, Samir Patel, Roland Coppens, Jacob Easaw, Kelvin Young
BACKGROUND: Temozolomide (TMZ) is an oral, systemic chemotherapy used chiefly for treating high-grade glioma. Due to the rising costs of systemic chemotherapy, many jurisdictions have replaced brand name with generic formulations. The aim of this study was to determine whether or not there was difference in the incidence of grade 3 or 4 bone marrow toxicity and median overall survival in patients treated with brand name versus generic TMZ in the province of Alberta, Canada. The province suspended the use of generic TMZ based on preliminary data pointing to excess toxicity...
April 2024: Neuro-oncology Practice
https://read.qxmd.com/read/38493896/recovery-of-measles-containing-and-hpv-vaccine-ordering-post-covid-19-pandemic-trends-by-public-vs-private-funding-source-urbanicity-and-state-united-states-january-2018-december-2022
#16
JOURNAL ARTICLE
Yoonjae Kang, Seth Meador, Carla Black, Tara Vogt
OBJECTIVE: To assess recovery in childhood and adolescent vaccine ordering since initial declines in 2020 due to COVID-19 pandemic-related disruptions. METHODS: Using vaccine ordering data provided by Merck & Co., Inc., Rahway, NJ, USA, the number of measles-containing vaccine doses ordered each month in the U.S. during January 1, 2020-May 31, 2022 were compared to doses ordered during the corresponding month in 2018 and human papillomavirus (HPV) vaccine doses ordered during January 1, 2020-December 31, 2022 were compared to corresponding month in 2019...
March 15, 2024: Preventive Medicine
https://read.qxmd.com/read/38464480/cemiplimab-in-locally-advanced-or-metastatic-cutaneous-squamous-cell-carcinoma-prospective-real-world-data-from-the-drug-access-protocol
#17
JOURNAL ARTICLE
Karlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, Vincent van der Noort, Henk M W Verheul, John B A G Haanen, Astrid A M van der Veldt, Ferry A L M Eskens, Maureen J B Aarts, Carla M L van Herpen, Mathilde Jalving, Jourik A Gietema, Lot A Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F Smit, Haiko J Bloemendal
BACKGROUND: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD from PD-1 blocker cemiplimab in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC; mCSCC). METHODS: Patients with laCSCC or mCSCC received cemiplimab 350 mg fixed dose every three weeks...
April 2024: The Lancet regional health. Europe
https://read.qxmd.com/read/38434097/extracorporeal-cardiopulmonary-resuscitation-for-refractory-out-of-hospital-cardiac-arrest-lessons-learned-from-recent-clinical-trials
#18
REVIEW
Stephanie DeMasi, Megan Donohue, Lisa Merck, Jarrod Mosier
Cardiac arrest is a leading contributor to morbidity and mortality in the United States. Survival has been historically dependent on high-quality cardiopulmonary resuscitation (CPR) and rapid defibrillation. However, a large percentage of patients remain in refractory cardiac arrest despite adherence to structured advanced cardiac life support algorithms in which these factors are emphasized. Veno-arterial extracorporeal membrane oxygenation is becoming an increasingly used rescue therapy for patients in refractory cardiac arrest to restore oxygen delivery by extracorporeal CPR (ECPR)...
April 2024: Journal of the American College of Emergency Physicians open
https://read.qxmd.com/read/38432247/cetuximab-versus-methotrexate-in-first-line-treatment-of-older-frail-patients-with-inoperable-recurrent-or-metastatic-head-and-neck-cancer-elan-unfit-a-randomised-open-label-phase-3-trial
#19
RANDOMIZED CONTROLLED TRIAL
Joël Guigay, Cécile Ortholan, Damien Vansteene, Didier Cupissol, Caroline Even, Marie-Christine Kaminsky, Christian Sire, Emmanuel Blot, Philippe Debourdeau, Laurence Bozec, Esma Saada-Bouzid, Jérôme Fayette, Pierre Dalloz, Yoann Pointreau, Hervé Le Caer, Claire Falandry, Laurence Digue, Antoine Braccini, Stéphane Lopez, Pierre Guillet, Cécile Michel, Nadir Cheurfa, Dominique Schwob, Jean Bourhis, Cécile Mertens, Anne Aupérin
BACKGROUND: At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population. METHODS: This randomised, open-label, phase 3 trial was done at 20 hospitals in France. Patients aged 70 years or older, assessed as frail by the ELAN Geriatric Evaluation, with recurrent or metastatic head and neck squamous cell carcinoma in the first-line setting and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 were eligible for inclusion...
March 2024: The Lancet. Healthy longevity
https://read.qxmd.com/read/38391232/orally-available-nucleoside-analog-umm-766-provides-protection-in-a-murine-model-of-orthopox-disease
#20
JOURNAL ARTICLE
Rajini R Mudhasani, Joseph W Golden, Gregory C Adam, Timothy J Hartingh, Krishna P Kota, David Ordonez, Corey R Quackenbush, Julie P Tran, Curtis Cline, Janice A Williams, Xiankun Zeng, David B Olsen, Linda A Lieberman, Christopher Boyce, Anthony Ginnetti, J Matthew Meinig, Rekha G Panchal, Eric M Mucker
Although smallpox has been eradicated, other orthopoxviruses continue to be a public health concern as exemplified by the ongoing Mpox (formerly monkeypox) global outbreak. While medical countermeasures (MCMs) previously approved by the Food and Drug Administration for the treatment of smallpox have been adopted for Mpox, previously described vulnerabilities coupled with the questionable benefit of at least one of the therapeutics during the 2022 Mpox outbreak reinforce the need for identifying and developing other MCMs against orthopoxviruses...
February 23, 2024: Microbiology Spectrum
keyword
keyword
3574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.